FDA Extends Review Period for Praxis' Relutrigine Application
The U.S. FDA has extended the review period for Praxis Precision Medicines' application for relutrigine, intended to treat SCN2A and SCN8A developmental and epileptic encephalopathies, by three months until December 27.
Tickers: $PRAX
Topics: drug approval neurological disorders